Ligand Pharmaceuticals Incorporated LGND
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) is a life-science royalty company. Its next catalyst on record is Qtorin rapamycin (Palvella) - microcystic LMs: PDUFA target action date (February 2027).
Upcoming catalysts
- February 2027Qtorin rapamycin (Palvella) - microcystic LMs — PDUFA target action date
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.
Next further out: Qtorin rapamycin (Palvella) - cutaneous venous malformations — Phase 3 trial initiation (Q4 2026). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Recent results and decisions
- Oct 29, 2026n/a Ligand acquired a royalty interest in Santen's Ryjunea.
We also continued to put capital to work in differentiated assets, acquiring a royalty interest in Santen's Ryjunea and entering into a structured financing agreement with AvenCell Therapeutics.
Filing - Oct 29, 2026n/a Ligand entered into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline.
Acquiring a royalty interest in Santen's Ryjunea and entering into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline.
Filing - Oct 29, 2026n/a Ligand entered into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline.
entering into a structured financing agreement with AvenCell Therapeutics to advance its next-generation CAR-T pipeline.
Filing
12 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.